| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.6 |
| mRNA | carboplatin:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |